Whatever the thoughts are about the Ximedica partnership with SLV or the delay of the financials today is that the value of Titan continues to increase. All it takes is one company to "overpay". Like I said earlier, maybe Ximedica picked up a nice chunk of that secondary offering - certainly would be attractive on the financials if you were considering taking a majority stake in XImedica.
As for Transenterix, they need to hire all those people b/c they don't know what they are doing. If I was a shareholder of Transenterix I wouldn't have a lot of faith when they give me a milestone of 510k approval and can't meet it.
IMO, when Titan releases their report: 1. Tissue validation completed and 2. Paperwork submitted for uplift to ny exchange
News 
Market Data 
Discover 
